The causal relation between human papillomavirus and cervical cancer

F X Bosch, A Lorincz, N Muñoz, C J L M Meijer, K V Shah

The causal role of human papillomavirus infections in cervical cancer has been documented beyond reasonable doubt. The association is present in virtually all cervical cancer cases worldwide. It is the right time for medical societies and public health regulators to consider this evidence and to define its preventive and clinical implications. A comprehensive review of key studies and results is presented.

INTRODUCTION

A major discovery in human cancer aetiology has been the recognition that cervical cancer is a rare consequence of an infection by some mucosatropic types of HPV. In public health terms, this finding is equally important as the discovery of the association between cigarette smoking and lung cancer, or between chronic infections with hepatitis B virus (HBV) or hepatitis C virus and the risk of liver cancer. Moreover, as in the HBV disease model, intense efforts are currently going into the development and testing of vaccines that may prevent the relevant HPV infections, and presumably, cervical cancer.

By the year 2000, the epidemiological evidence included a large and consistent body of studies indicating, beyond any reasonable doubt, strong and specific associations relating HPV infections to cervical cancer. The observations have been reported from all countries where investigations have taken place. Studies include prevalence surveys, natural history investigations, case–control studies and, more recently, a randomised intervention trial. Natural history and follow up studies have clearly shown that HPV infection preceded the development of cervical cancer by several years and confirmed that sexual transmission is the predominant mode of HPV acquisition. These studies satisfied, in biological terms, the long known clinical and epidemiological observations that cervical cancer displayed the profile of a sexually transmitted disease (STD). Case–control studies, case series, and prevalence surveys have unequivocally shown that HPV DNA can be detected in adequate specimens of cervical cancer in 90–100% of cases, compared with a prevalence of 5–20% in cervical specimens from women identified as suitable epidemiological controls.

The association has been recognised as causal in nature by several international review parties since the early 1990s, and the claim has been made that this is the first necessary cause of a human cancer ever identified.

SUMMARY

During the 1990s, epidemiological studies, supported by molecular technology, provided evidence on the causal role of some human papillomavirus (HPV) infections in the development of cervical cancer. This association has been evaluated under all proposed sets of causality criteria and endorsed by the scientific community and major review institutes. The finding is universally consistent, and to date there are no documented alternative hypotheses for the aetiology of cervical cancer.

HPV has been proposed as the first ever identified, “necessary cause” of a human cancer. In practical terms, the concept of a necessary cause implies that cervical cancer does not and will not develop in the absence of the persistent presence of HPV DNA.

Cervical cancer is still the second most common cancer in women worldwide, although it is a theoretically preventable disease.

In developed parts of the world, and in populations where cytology based programmes are established, it would be beneficial to add HPV testing to the screening protocol. HPV testing was shown by several studies, including one randomised trial, to be of help in solving the ambiguous cases generated by cytology reading.

In populations where cytology programmes are either not in place or are not efficient, HPV testing should now be considered and evaluated as an alternative test for primary screening.

Prevention of exposure to high risk HPV types by vaccination may prove to be the most efficient and logistically feasible preventive intervention for cervical cancer.

At this stage of development, regulatory agencies are requested to evaluate the scientific evidence and weigh its implications in relation to costs, public health investments, and policy. This is a subjective evaluation that could be guided by a careful description of the most relevant studies and findings.

See end of article for authors’ affiliations

Correspondence to:
Dr F X Bosch,
Epidemiology and Cancer Registry Unit (SERC),
Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, Gran Via km 2,7, L’Hospitalet de Llobregat, 08907
Barcelona, Spain;
x.bosch@ico.scs.es

Accepted for publication
22 January 2002

Abbreviations: AF, attributable fraction; ASCUS, atypical squamous cells of undetermined significance; CI, confidence interval; CIN, cervical intraepithelial neoplasia; EBV, Epstein-Barr virus; GP, general primer; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; HSIL, high grade squamous intraepithelial lesion; HSV-2, type 2 herpes simplex virus; IARC, International Agency for Research on Cancer; IBSCC, international biological study on cervical cancer; OC, oral contraceptive; OR, odds ratio; ORF, open reading frame; Pap, Papanicolaou; PD, protective fraction; PCR, polymerase chain reaction; RB, retinoblastoma; RR, relative risk; STD, sexually transmitted disease; Th1, T helper cell type 1
The implications of the recognition that, in the absence of viral DNA, cervical cancer does not develop, are of considerable practical importance. On the one hand, the concept of risk groups comes into focus. High risk women can now be sharply redefined as the group of persistent HPV carriers. Operatively, this represents substantial progress from previous versions of the high risk group that identified women by their exposure to a constellation of ill defined factors (low socioeconomic status, high number of sexual partners, smoking, use of oral contraceptives, history of STDs, and any combination of the above). Most of these factors are now viewed either as surrogates of HPV exposure or as relevant cofactors given the presence of HPV DNA. On the other hand, if indeed HPV is a necessary cause of cervical cancer, the implication is that specific preventive practices targeting some putative non-HPV related cervical cancer cases are no longer justified. Finally, technology is now available to screen HPV DNA positive women in the general population. Therefore, the final consideration on the nature of the association between HPV and cervical cancer is of considerable public health relevance. Research at the population level has largely accomplished its task by providing an exhaustive body of evidence. It is now time for public health institutions to evaluate these achievements, consider the costs and benefits involved, and apply this knowledge to their guidelines, recommendations, and policy.

HISTORICAL OVERVIEW

Research in relation to the aetiology of cervical cancer has made substantial progress in the past two decades, both in scientific and operational terms. For decades, the epidemiological profile of women with cervical cancer was recognized as suggestive of a sexually transmitted process, and several infectious agents were proposed over the years including syphilis, gonorrhea, and type 2 herpes simplex virus (HSV-2).

The development of technology to test for the presence of HPV DNA in cellular specimens in the early 1980s and the multidisciplinary collaboration within the field made possible the establishment of a definite aetiologic role for HPV in cervical cancer. Evidence is also accumulating for HPV involvement in a considerable proportion of cancers of the vulva, vagina, anal canal, perianal skin, and penis. The association of HPV with cervical cancer has provided the background and the justification for improving screening programmes and for developing HPV vaccines.

Figure 1 is a schematic view of the time scale of this dynamic process. It includes an indication of the results obtained as technology evolved in sensitivity expressed as the per cent of cervical cancer cases that were found to contain viral DNA. The figure also indicates the types of HPV tests that were predominantly used and an estimate of the periods in which the key types of studies were initiated.

Figure 2 displays the approximate number of scientific papers identified by Medline searches on HPV and on HPV and cervical cancer, and the number of research abstracts presented at the major annual papillomavirus conferences (http://www.ipvsoc.org). The 1980s generated a rapidly increasing number of publications on HPV DNA prevalence in cervical cancer and reports on validation of the available detection methods. The 1990s produced the key results of case–control and cohort studies, and beginning in the late 1990s there was an increasing number of publications on the clinical uses of HPV testing in screening and triage.

CAUSALITY CRITERIA IN HUMAN CANCER RESEARCH

Epidemiological studies are essential to establish the association between risk factors and cancer and to qualify the nature of the association. Traditionally, these include case series, case–control studies, cohort studies, and intervention studies.

Comparisons of exposure between patients with cervical cancer and their relevant controls were initially established using questionnaires. Most studies conducted before the availability of HPV DNA detection systems identified as key risk factors several variables related to the sexual behaviour of the women and of their sexual partners. The most frequently reported risk factors included the number of sexual partners, an early age at first intercourse, or any previous STD.

Once the relevant biomarkers were validated, in this case the presence of HPV DNA in exfoliated cervical cells, it became possible to advance over questionnaire based studies and establish biologically sound comparisons between patients and controls. In epidemiological terms, these comparisons would analyse cervical cells from women with cervical cancer and from otherwise comparable women without cervical cancer (case–control studies), or from cohorts of women tested for viral DNA (cohort studies). To characterize the link between HPV and invasive cervical cancer, case–control studies proved to be the key study design and the only ones ethically acceptable in human populations. Typically in such a study and at the time of fieldwork, controls are selected to match the age distribution of the cases and, as much as possible, the general characteristics of the cases (place of residence, socioeconomic status, health plan, etc.). To characterize the association, all study participants are requested to comply with a questionnaire to assess their individual exposure to any known or suspected risk factor for the disease. The information is then used to estimate the odds ratios (ORs) of disease related to any given exposure. Multivariate analyses have the ability to compare (through statistical adjustment) strictly equivalent groups of women in relation to any of the exposures of interest. The adjusted differences (ratios) in the

![Figure 1](http://www.jclinpath.com)  
**Figure 1** Evolution of epidemiological research on human papillomavirus (HPV) and cervical cancer in the past two decades. FISH, filter in situ hybridisation; GP-PCR, general primer PCR; HC I-II, hybrid capture first and second generation; PCR, polymerase chain reaction; SH, Southern blot hybridisation; TS-PCR, type specific PCR.

![Figure 2](http://www.jclinpath.com)  
**Figure 2** Scientific publications on human papillomavirus (HPV) identified by Medline and the number of research abstracts presented at the annual Papillomavirus International Conferences.
prevalence in HPV markers between cases and controls are then obtained after having eliminated the effects of any other differences in exposure. Likewise, comparisons of cases and controls in relation to other variables of interest will provide estimates of the relevance of other factors (oral contraceptives (OCs) or smoking) and identify the variables that merely reflect HPV exposure (surrogate variables).

When the technology to detect HPV DNA in samples of DNA extracted from exfoliated cervical cells became available, it was relatively easy to show that most of the sexual behaviour variables were in fact surrogate measures of HPV exposure, reflecting the predominant pathway of acquisition of HPV. As methods became more sensitive, the parameters that merely expressed the probability of HPV (or any other STD) infection, such as number of sexual partners, became statistically irrelevant.2-5

Causality in public health requires a judgment based on scientific evidence from human and experimental (animal) observations. As such, only the latter may benefit from the most stringent criteria of causality; that is, the repeated induction of the disease by exposure to the relevant agent(s) compared with the “spontaneous” occurrence of the same disease in unexposed and yet comparable groups of animals. All causal associations of human cancers have been recognised based on educated judgment of the results of epidemiological studies at the level already available for HPV and cervical cancer. Final proof can only be confirmed by intervention (preventive) trials, in which a reduction of the disease burden (incidence or mortality) is observed following the introduction of a preventive practice in strictly controlled conditions. These studies typically include as controls populations to whom the existing standard of preventive care is being offered.

Table 1 displays some of the criteria that have been proposed to evaluate the nature of the associations encountered by epidemiological studies. This is particularly relevant when causality is being proposed because, as a consequence, preventive or clinical recommendations are made.

In addition to the criteria listed in Table 1, some additional contributions might be worth discussing. In 1976, Evans reviewed the history of the causality criteria in infectious disease models and adapted the early postulates of Henle-Koch to both the viral origin of acute diseases and to the relation between viral infections and cancer.14 The human models that inspired most of the latter included two examples: Epstein-Barr virus (EBV) infections and Burkitt’s lymphoma, and HSV-2 viral infections and cervical cancer. The technology that was discussed was largely based on antibody detection and the studies involved were seroepidemiological surveys and case-control studies. Antibody measurements were the methods of choice for the assessment of exposure. Evans proposed a unified scheme for causation that included most of the criteria mentioned in table 1.14 In 1976, Rothman15 introduced the concepts of “necessary and sufficient causes”. This model is useful to accommodate the growing evidence of the multifactorial origin of human cancer in many instances. Finally, several authors have defined criteria to evaluate the findings of molecular technology that provided the basis of the studies of HPV and cervical cancer.16-17

Because of its wider acceptance, we will discuss in detail the criteria proposed by Hill, and its version adopted by the International Agency for Research on Cancer (IARC) monograph programme, in addition to the model on necessary and sufficient causes proposed by Rothman in 1995.18

In brief, the criteria proposed by Hill19 as summarised by Rothman20 include the following:

Hill suggested that the following aspects of an association should be considered when attempting to distinguish causal from non-causal associations: (1) strength, (2) consistency, (3) specificity, (4) temporality, (5) biological gradient, (6) plausibility, (7) coherence, (8) experimental evidence, and (9) analogy.

**Strength**

By “strength of association”, Hill means the magnitude of the ratio of incidence rates. Hill’s argument is essentially that strong associations are more likely to be causal than weak associations because if they were the result of confounding or some other bias, the biasing association would have to be even stronger and would therefore presumably be evident. Weak associations, on the other hand, are more likely to be explained by undetected biases. Nevertheless, the fact that an association is weak does not rule out a causal connection.

**Consistency**

Consistency refers to the repeated observation of an association in different populations under different circumstances.

**Specificity**

The criterion of specificity requires that a cause should lead to an effect that is not multiple effects. However, causes of a given effect cannot be expected to be without other effects on any logical grounds. In fact, everyday experience teaches us repeatedly that single events may have many effects.

<table>
<thead>
<tr>
<th>Table 1 Epidemiological considerations important for causal inference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Magnitude of effect</strong></td>
</tr>
<tr>
<td><strong>Consistency</strong></td>
</tr>
<tr>
<td><strong>Temporality</strong></td>
</tr>
<tr>
<td><strong>Dose response</strong></td>
</tr>
<tr>
<td><strong>Biological mechanism</strong></td>
</tr>
<tr>
<td><strong>Experimentation</strong></td>
</tr>
<tr>
<td><strong>Exclusion of alternative explanations</strong></td>
</tr>
</tbody>
</table>

Adapted from Weed 1995.12
**Temporality**

Temporality refers to the necessity that the cause should precede the effect in time. The temporality of an association, is a sine qua non: if the “cause” does not precede the effect that is indisputable evidence that the association is not causal.

**Biological gradient**

Biological gradient refers to the presence of a dose–response curve. If the response is taken as an epidemiological measure of effect, measured as a function of comparative disease incidence, then this condition will ordinarily be met.

**Plausibility**

Plausibility refers to the biological plausibility of the hypothesis, an important concern but one that may be difficult to judge.

**Coherence**

Taken from the Surgeon General’s report on Smoking and Coherence:

“Plausibility refers to the biological plausibility of the hypothesis, an important concern but one that may be difficult to judge.”

**Experimental evidence**

Such evidence is seldom available for human populations. In human data, the experimental criterion takes the form of preventive interventions and explores whether there is evidence that a reduction in exposure to the agent is associated with a reduction in risk.

**Analogy**

The insight derived from analogy seems to be handicapped by the inventive imagination of scientists, who can find analogies everywhere. Nevertheless, the simple analogies that Hill offers—if one drug can cause birth defects, perhaps another can also—could conceivably enhance the credibility that an association is causal.

As is evident, these nine aspects of epidemiological evidence offered by Hill to judge whether an association is causal are saddled with reservations and exceptions; some may be wrong (specificity) or occasionally irrelevant (experimental evidence and perhaps analogy). Hill admitted that: “none of my nine viewpoints can bring indisputable evidence for or against the cause and effect hypothesis and none (except temporality) can be required as a sine qua non”.

The IARC in its monograph programme largely adopted the causality criteria proposed by Hill and established rules to decide on the carcinogenicity of a given exposure, particularly when human data are scarce and must be combined with experimental data. However, the final qualification of the carcinogenicity of any given substance being evaluated is taken by vote of the external (non-IARC) participants.

The monograph programme and its criteria has been reviewed and accepted by most scientists in the field of human carcinogenesis. To date, 77 monographs have been published, of which five involve biological agents such as HPV.

In its preamble, the monograph programme establishes guidelines to qualify an epidemiological observation as causal, and also defines rules to be followed when human data suggest lack of carcinogenicity potential. These criteria are useful to challenge any aetiological hypothesis when the epidemiological studies are inconsistent or when only weak associations are reported.

Finally, another useful way of examining the nature of an association was provided by a model system that proposed that any given disease would occur as a consequence of human exposure to a “sufficient cause”. A sufficient cause is described, in its simplest model, as the concurrence in a given individual of a constellation of factors (called the components of the sufficient cause), following which the disease will develop. Each given disease will have its own sufficient cause or sets of sufficient causes (lung cancer may have a sufficient cause that involves cigarette smoking, but another sufficient cause that does not include smoking, such as intense radon exposure in non-smokers). According to the model, a necessary cause is described as a component of a sufficient cause that is part of all the sufficient causes described. To prevent disease it is not necessary to identify all the components of a sufficient cause, or to remove them all: it is sufficient to remove one component from each sufficient cause, that is to remove, if it exists, the necessary cause.

**COMPLIANCE OF THE CAUSALITY CRITERIA IN THE HPV AND CERVICAL CANCER MODEL**

In the following sections, we will review several studies that have provided evidence of the association between HPV and cervical cancer, using the criteria outlined in table 1. For purposes of clarity, we shall concentrate the discussion on the criteria that have proved to be of greater value in the evaluation of human carcinogens and on the studies that focused on invasive cervical cancer.

**Strength of the association**

This criterion is usually discussed by examining the magnitude of the relative risk (RR), or the OR, which is the estimate of the RR in case–control studies. We shall use as the primary example the results of the IARC multicentre case–control study on invasive cervical cancer, as presented at international scientific meetings, and either published or at different stages of preparation for publication. In brief, this project included nine case–control studies in different parts of the world, mostly in high risk countries. HPV DNA testing was done in two central research laboratories using the MYO9/11 primer (GP) GP5+/6+ PCR polymerase chain reaction (PCR) testing systems. The published results have reported ORs for cervical cancer in the range of 50 to 100 fold for HPV DNA. ORs for specific associations (such as HPV-16 and squamous cell cancer and HPV-18 and cervical adenocarcinomas) range between 100 and 900. These estimates lead to calculations of attributable fractions (AF) for the entire study greater than 95%.

**Table 2** Size of the IARC multicentre case–control study and human papillomavirus (HPV) DNA prevalence

<table>
<thead>
<tr>
<th>HPV DNA prevalence</th>
<th>Controls</th>
<th>Cervical cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Adeno and mixed</td>
</tr>
<tr>
<td>No. countries N</td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Brazilian, Morocco, Paraguay, the Philippines, Thailand, Peru, Mali, Spain, and Colombia.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil, Morocco, Paraguay, the Philippines, Thailand, and Peru.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HPV DNA (%) +ve</th>
<th>2491</th>
<th>13.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV DNA (%) +ve</td>
<td>1466</td>
<td>15.4</td>
</tr>
<tr>
<td>HPV DNA (%) +ve</td>
<td>2365</td>
<td>90.7</td>
</tr>
<tr>
<td>HPV DNA (%) +ve</td>
<td>2280</td>
<td>96.6</td>
</tr>
</tbody>
</table>

*Brazil, Morocco, Paraguay, the Philippines, Thailand, Peru, Mali, Spain, and Colombia. 
†Brazil, Morocco, Paraguay, the Philippines, Thailand, and Peru.
these very high ORs reflect the risk in relation to existing HPV DNA in cervical cells (HPV DNA point prevalence), not in relation to “ever” being infected with HPV (cumulative lifetime exposure). Furthermore, if HPV shedding was intermittent among controls, their corresponding HPV prevalence would have been underestimated, resulting in an inflation of the ORs observed. It is usually interpreted that the HPV DNA point prevalence at advanced age (over 40 years of age) reflects viral persistency. However, much research is still devoted to defining viral persistency and its prognosis accurately, a crucial definition for the clarification of the uses of HPV testing in screening and patient management.

Most of the discussion in the text uses HPV DNA as a generic marker that includes any positive result for several HPV types. It is now possible to provide estimates of the RR for at least 10 different HPV types showing that there are no significant differences in the risk of cervical cancer in relation to the HPV types most commonly found in these lesions. The preliminary results of the IARC multicentre case–control were pooled and summarised by Muñoz et al in 2000, at the HPV 2000 Papillomavirus Conference (www.hpv2000.com). These analyses indicated that for squamous cell carcinomas, the age and centre adjusted OR was 83.3 (95% CI, 54.9 to 105.3). The prevalence of the four most common HPV types and their ORs among 1545 cases with single infections were: HPV-16, 59% (OR = 148); HPV-18, 12% (OR = 77.6); HPV-31, 3.7% (OR = 71.5). Other less common HPV types showing equally high ORs were: HPV-33, OR = 148; and HPV-31, 3.7% (OR = 71.5). HPV-18, 12% (OR = 77.6). HPV-35, OR = 34.8; HPV-51, OR = 42.7; HPV-52, OR = 145.7; HPV-58, OR = 78.9; and HPV-59, OR = 347.3.

Most of the common types among cases were also the most common types among HPV positive control women: HPV-16, 30.3%; HPV-18, 8.2%; HPV-31, 4.8%; and HPV-45, 4.8%. These findings indicate that in addition to HPV-16 and HPV-18, HPV types 31, 33, 35, 51, 52, 58, and 59 should be considered as human carcinogens.

The HPV type distribution in the population and in patients with cervical cancer shows a seemingly modest geographical variability that has not been fully described (J Kornegay, personal communication, 2001). The description and the implications of such variability for HPV testing and HPV vaccination are to be determined.

The results of the multicentre study are consistent with findings from other countries that have generated recent data on invasive cervical cancer and preinvasive disease in Costa Rica, Paraguay, Morocco, and Peru have generated recent data on invasive cervical cancer and preinvasive disease in Costa Rica, Paraguay, Morocco, and Peru have generated recent data on invasive cervical cancer and preinvasive disease. Further, the multicentric study is consistent with findings from other countries that have generated recent data on invasive cervical cancer and preinvasive disease in Costa Rica, Paraguay, Morocco, and Peru. These findings indicate that in addition to HPV-16 and HPV-18, HPV types 31, 33, 35, 51, 52, 58, and 59 should be considered as human carcinogens.

The HPV type distribution in the population and in patients with cervical cancer shows a seemingly modest geographical variability that has not been fully described (J Kornegay, personal communication, 2001). The description and the implications of such variability for HPV testing and HPV vaccination are to be determined.

The results of the multicentre study are consistent with findings from other countries that have generated recent data on invasive cervical cancer and preinvasive disease in Costa Rica, Paraguay, Morocco, and Peru. These findings indicate that in addition to HPV-16 and HPV-18, HPV types 31, 33, 35, 51, 52, 58, and 59 should be considered as human carcinogens.

The HPV type distribution in the population and in patients with cervical cancer shows a seemingly modest geographical variability that has not been fully described (J Kornegay, personal communication, 2001). The description and the implications of such variability for HPV testing and HPV vaccination are to be determined.

The results of the multicentre study are consistent with findings from other countries that have generated recent data on invasive cervical cancer and preinvasive disease in Costa Rica, Paraguay, Morocco, and Peru. These findings indicate that in addition to HPV-16 and HPV-18, HPV types 31, 33, 35, 51, 52, 58, and 59 should be considered as human carcinogens.

Table 2 shows the size of the multicentre case–control study and the prevalence of HPV DNA in each relevant group. Figure 3 displays the HPV DNA prevalence in eight countries in cervical cancer cases and controls. It is noteworthy that the first two studies conducted in Spain and Colombia (fig 3) used early versions of the MYO9/11 PCR system that identified HPV DNA in approximately 75% of the cases. The rest of the studies were analysed using the GP5+/6+ PCR system and its modifications, which resulted in an almost 20% increase in the HPV DNA detection rate.

Table 3 shows the corresponding estimates of the RR (OR and 95% confidence interval (CI)). Results are presented separately for squamous cell carcinomas and adenocarcinomas of the cervix. Given the case–control design of the study, the results shown in Table 3 do not represent true prevalences, but rather the risk of cervical cancer in relation to the HPV DNA positivity in the control group. The risk of cervical cancer associated with the HPV DNA positivity in the control group was assessed using the odds ratio (OR).

Table 3 indicates the corresponding estimates of the RR (OR and 95% confidence interval (CI)). The odds ratio is a measure of the risk of cervical cancer in relation to the HPV DNA positivity in the control group. The ORs shown in Table 3 are estimated using the Mantel-Haenszel method, which is used to estimate the overall OR across studies and particularly in relation to the HPV detection method used. Table 3 provides an indication of the proportion of HPV DNA positive controls among the study populations. The proportion of HPV DNA positive controls varies across studies and particularly in relation to the HPV detection method used. Table 4 provides an indication of the proportion of HPV DNA positive controls among the study populations.
of specimens from cases and from the general population that showed multiple types. The table suggests that populations at high risk of cervical cancer and with high rates of human immunodeficiency virus (HIV) positivity tend to show higher proportions of multiple types than do populations not belonging to these risk groups. Longitudinal studies have suggested that the one time, cross sectional detection of type specific HPV may underestimate the cumulative lifetime diversity of exposure to HPV.11 However, in all studies of invasive carcinoma, the risk linked to multiple HPV types does not vary significantly from the risk linked to single HPV types.

The similarity in the prognostic value of detection of any of the 10 high risk HPV types, in addition to any combination of them, clearly indicates that group testing for high risk HPV would be sufficient in the context of clinical and screening protocols.

Figure 4 shows, for comparison purposes, some estimates of the strength of associations between environmental factors and human cancer that were recognised as causal in nature by epidemiological studies and subsequently proved in human populations by intervention studies. The figure includes risk (RRs or ORs) as the measurement of the strength of the associations found in case–control studies using PCR methods between human papillomavirus 16 (HPV-16) (or its nearest surrogate) and invasive cervical cancers. *The OR estimate is = owing to the absence of HPV positive controls. Adapted from IARC monograph 64, 1995.12

Conistency

There is a striking consistency between the results of the multicentre case–control study and over 50 other studies conducted in other countries, under different protocols and HPV-DNA testing systems. Figures 5, 6, and 7 summarise the results of studies that compared the prevalence of HPV DNA in patients with cervical cancer and controls. Some of the studies used the prevalence of HPV-16 DNA to calculate ORs and some reported results for HPV DNA (all types combined). Some studies focused on invasive cervical cancer, whereas others used preinvasive lesions as the definition of cases. When indicated, separate analyses are presented for squamous cell carcinomas and for adenocarcinomas. Studies that have compared risk factors for cervical intraepithelial neoplasia stage 3 (CIN 3) and invasive cancer have not reported any significant differences in their associations with HPV or with their epidemiological profile.13 14

Apart from confirming the high ORs shown in figs 5 and 6, fig 7 also demonstrates the consistency of results between

Strength of association. Evaluation

The association between HPV DNA in cervical specimens and cervical cancer is one of the strongest ever observed for a human cancer. HPV-16 accounts for almost 50% of the types identified in cervical cancer. The cancer risk for any one of at least 10 HPV types or for any combination of HPV types does not differ significantly.

| Odds ratio (OR) and 95% confidence intervals for associations found in case–control studies using PCR methods between human papillomavirus 16 (HPV-16) (or its nearest surrogate) and invasive cervical cancers. *The OR estimate is = owing to the absence of HPV positive controls. Adapted from IARC monograph 64, 1995.12

Consistency

There is a striking consistency between the results of the multicentre case–control study and over 50 other studies conducted in other countries, under different protocols and HPV-DNA testing systems. Figures 5, 6, and 7 summarise the results of studies that compared the prevalence of HPV DNA in patients with cervical cancer and controls. Some of the studies used the prevalence of HPV-16 DNA to calculate ORs and some reported results for HPV DNA (all types combined). Some studies focused on invasive cervical cancer, whereas others used preinvasive lesions as the definition of cases. When indicated, separate analyses are presented for squamous cell carcinomas and for adenocarcinomas. Studies that have compared risk factors for cervical intraepithelial neoplasia stage 3 (CIN 3) and invasive cancer have not reported any significant differences in their associations with HPV or with their epidemiological profile.13 14

Apart from confirming the high ORs shown in figs 5 and 6, fig 7 also demonstrates the consistency of results between
squamous cell carcinomas and adenocarcinomas, the consistency of findings between preneoplastic disease and invasive cancer, and the consistency of findings between risk estimates for HPV DNA (all types considered) and risk estimates restricted to high risk types.

**Consistency. Evaluation**

The association between HPV DNA in cervical specimens and cervical cancer is consistent in a large number of investigations in different countries and populations. There are no published studies with observations challenging the central hypothesis on causality.

**Specificity**

Specificity, as defined by Hill, tended to be relegated to a secondary level for cancer causality evaluation once it became clear that carcinogenic exposures are usually complex (for example, cigarette smoke) and can induce cancer in different organs and even cancers of different histological profile in the same organ.

In the case of HPV, the complexity of the association is being unveiled. The HPV family includes over 100 HPV types, of which 30–40 are mucosatropic and at least 15 types have been clearly linked to cervical cancer. In addition, some of these types are also related to other cancers of the genital tract (vulvar cancer, vaginal cancer, and cancers of the anal canal, perianal skin, and the penis) and perhaps to cancers of other organs (such as oropharyngeal and skin cancer).

To examine the association of HPV and human cancer in light of the specificity criteria, we shall widen the original scope (one exposure/one disease) to verify whether a more complex model involving multiple HPV types and several cancer sites seems to occur with frequencies suggesting a consistent departure from a random model.

1. About 15 HPV types are involved in over 95% of the cervical cancer cases. HPV-16 and HPV-18 are the most common types identified and represent 50% and 10%, respectively, of the viral types involved in invasive cancer. Figure 8 shows the cumulative prevalence of five HPV types in cervical carcinomas by histological type in 2400 cases included in the multicentre case–control study. It clearly shows that these five HPV types comprise 80–95% of the viral types identified in carcinomas.

2. Adenocarcinomas and adenosquamous cell carcinomas are more closely related to HPV-18 and its phylogenetically related family (HPV types 39, 45, and 59) than are squamous cell carcinomas, which in turn are closely linked to HPV-16 and its phylogenetically related family (HPV types 31, 35, and 52). The reasons for such specificity are unknown.

3. Cancers of the vulva and vagina are closely related to HPV-16. Approximately 40–50% of vulvar cancer shows HPV DNA, and in several series HPV-16 is by far the predominant type in more than 80% of cases.

4. Cancer of the tonsil is closely related to HPV-16, whereas other cancers of the oral cavity show inconsistent and lower prevalences of HPV DNA.

5. Skin cancers related to the epidermodysplasia verruciformis condition are related to a restricted number of dermatotrophic HPV types. These are also recovered from basal cell carcinomas and squamous cell carcinomas of the skin in immunosuppressed and immunocompetent individuals.

6. Other associations, reported in a small number of cases, seem to occur with some specificity. For example HPV-16 and cancers of the conjunctiva and HPV-16 and cancers of the ungual bed.

7. Studies on HPV variants (variation within HPV types at the single nucleotide level) are beginning to unveil risk differences. The geographical distribution of HPV variants and its relevance for HPV testing and for vaccine development are still uncertain.

8. HPV has been excluded as a likely cause or even as a risk factor for other human cancers. A large number of investigations (largely unpublished) have not provided support to the hypothesis of the involvement of these viruses in the causation of cancers of the endometrium, ovary, prostate, or other sites (reviewed by Shah and Howley and Syrjänen and Syrjänen).

**Figure 7** Odds ratios (OR) and 95% confidence intervals for associations found in case–control studies after the year 2000. HPV, human papillomavirus.

**Figure 8** Cumulative prevalence of human papillomavirus (HPV) types in cervical cancer. Taken from the IARC multicentre case–control study; preliminary data.
In conclusion, although the specificity criteria can be viewed as of secondary applicability, the global picture indicates that HPV types are not randomly associated with human cancer. A fair degree of specificity is consistently reported, even if the complexities of the type specific viral properties and of the organ/cell susceptibility have not been fully disclosed.

**Temporality**
Of the criteria outlined by Hill and repeatedly endorsed by the IARC monograph programme and other bodies, the demonstration that exposure has occurred before the diagnosis is considered a “sine qua non” condition for a risk factor and for establishing causality. Five groups of studies have contributed data relevant to the temporality criterion.

**Descriptive data**
Cross sectional studies have repeatedly reported that subclinical HPV infections are highly prevalent in young individuals, whereas invasive cervical cancer typically develops in the third decade and later (fig 9). The cross sectional prevalence of HPV DNA decreases spontaneously to a background level of 2–8% in most populations in groups that are 40 years old and above. In countries where intensive screening of young women takes place, part of the HPV prevalence reduction could be attributable to aggressive treatment of HPV related cervical lesions. Women who remain chronic HPV carriers are currently allowed to continue beyond the stage of HSIL/CIN 3 or carcinoma in situ. This is because even in controlled settings, observations are not consistent with the cross sectional profile displayed in fig 9. However, the currently observed time intervals may still suffer from imprecision in the estimates of time at first exposure, from the variability in the endpoint definition, and from censoring as a result of treatment of the early lesions. Follow up studies of women with and without cervical abnormalities have indicated that the continuous presence of HR-HPV is necessary for the development, maintenance, and progression of progressive CIN disease. A substantial fraction (15–30%) of women with HR-HPV DNA who are cytologically normal at recruitment will develop CIN 2 or CIN 3 within the subsequent four year interval. Conversely, among women found to be HR-HPV DNA negative and cytologically identified as either atypical squamous cells of undetermined significance (ASCUS) or borderline or mild dysplasia, CIN 2/3 is unlikely to develop during a follow up of two years, and their cytology is likely to return to normal. Women found positive for low risk HPVs rarely become persistent carriers and their probability of progression to CIN 2/3 is extremely low.

As ongoing cohorts expand their follow up time, more precise estimates are being provided on the predictive value of viral persistence as defined by repeated measurements of viral types and variants. One such cohort in Sao Paulo has shown that the incidence of cervical lesions in women who were HPV negative twice was 0.73/1000 women months. The corresponding incidence among women with repeated HPV-16 or HPV-18 positive results was 8.68, a 12 fold increased incidence. The OR for HPV persistence among women who were twice HPV positive for the same oncogenic types was OR = 41.2 (95% CI, 10.7 to 158.3). Retrospective assessment of HPV status using archival smears from cases of cervical cancer and controls has provided evidence that HPV DNA preceded the development of invasive disease, and showed its value in signalling false negatives smears. An interesting observation from the same group suggests that the clearance of HR-HPV in otherwise established cytological lesions is a marker associated with the regression of CIN lesions. Finally, the persistence of HPV DNA after treatment for CIN 2/3 is an accurate predictor of relapse, and is at least as sensitive as repeated vaginal cytology.

These results are useful in defining the clinical role of HPV testing. However, most observations on preinvasive disease have limitations for making inferences on cervical cancer causality. This is because even in controlled settings, observations are not allowed to continue beyond the stage of HSIL/CIN 3 or carcinoma in situ.

**Follow up studies**
For cervical cancer, compliance with the temporality criteria has been established by numerous cohort studies that monitored women from cytological normalcy to the stage of high grade cervical intraepithelial neoplasia (high grade squamous intraepithelial lesions (HSIL) or CIN 2/3). Monitoring of women to invasive disease is not acceptable on ethical grounds and thus that information is not available.

Repeated sampling of women being followed for viral persistence and cervical abnormalities has shown that the median duration of the infections is around eight months for high risk HPV types, compared with 4.8 months for the low risk HPV types. In two unrelated studies, the time estimates were fairly consistent. In one study in a high risk population in Brazil, the mean duration of HPV detection was 13.5 months for high risk HPV types and 8.2 months for the non-oncogenic types. HPV-16 tended to persist longer than the average for high risk types other than HPV-16. The results were remarkably similar in a student population in the USA and in the UK. The self limiting course of most HPV infections is consistent with the cross sectional profile displayed in fig 9. However, the currently observed time intervals may still suffer from imprecision in the estimates of time at first exposure, from the variability in the endpoint definition, and from censoring as a result of treatment of the early lesions. Follow up studies of women with and without cervical abnormalities have indicated that the continuous presence of HR-HPV is necessary for the development, maintenance, and progression of progressive CIN disease. A substantial fraction (15–30%) of women with HR-HPV DNA who are cytologically normal at recruitment will develop CIN 2 or CIN 3 within the subsequent four year interval. Conversely, among women found to be HR-HPV DNA negative and cytologically identified as either atypical squamous cells of undetermined significance (ASCUS) or borderline or mild dysplasia, CIN 2/3 is unlikely to develop during a follow up of two years, and their cytology is likely to return to normal. Women found positive for low risk HPVs rarely become persistent carriers and their probability of progression to CIN 2/3 is extremely low.

As ongoing cohorts expand their follow up time, more precise estimates are being provided on the predictive value of viral persistence as defined by repeated measurements of viral types and variants. One such cohort in Sao Paulo has shown that the incidence of cervical lesions in women who were HPV negative twice was $0.73/1000$ women months. The corresponding incidence among women with repeated HPV-16 or HPV-18 positive results was $8.68$, a $12$ fold increased incidence. The OR for HPV persistence among women who were twice HPV positive for the same oncogenic types was $\text{OR} = 41.2$ ($95\% \text{ CI}, 10.7 \text{ to } 158.3$). Retrospective assessment of HPV status using archival smears from cases of cervical cancer and controls has provided evidence that HPV DNA preceded the development of invasive disease, and showed its value in signalling false negatives smears. An interesting observation from the same group suggests that the clearance of HR-HPV in otherwise established cytological lesions is a marker associated with the regression of CIN lesions. Finally, the persistence of HPV DNA after treatment for CIN 2/3 is an accurate predictor of relapse, and is at least as sensitive as repeated vaginal cytology.

These results are useful in defining the clinical role of HPV testing. However, most observations on preinvasive disease have limitations for making inferences on cervical cancer causality. This is because even in controlled settings, observations are not allowed to continue beyond the stage of HSIL/CIN 3 or carcinoma in situ.

**Retrospective cohorts**
A particularly interesting approach to conducting follow up studies of invasive cancer (as opposed to studies of CIN 3)
without ethical and time constraints is provided by so called “nested case–control studies”. These are studies initiated several years in the past that assembled and stored large banks of biological specimens from healthy individuals. Linkage studies can then identify cases of cervical cancer (or any other condition) that have occurred in the interval and the original specimens can then be analysed for the presence of HPV biomarkers. HPV DNA prevalence can then be compared with the corresponding prevalence in specimens of epidemiologically sound controls (individuals from the same cohort who did not develop the condition under otherwise equivalent exposures). These studies have documented the existence of HPV exposure years before the development of the disease, thus reproducing the conditions of a longitudinal study. With this approach, a RR estimate of 16.4 (95% CI, 4.4 to 75.1) was seen for invasive cervical cancer in Sweden using DNA extracted from stored Papanicolaou (Pap) smears, and a RR of 32 (95% CI, 6.8 to 153) was seen in the Netherlands. In a similar study design, an OR of 2.4 (95% CI, 1.6 to 3.7) was obtained using serological markers of HPV exposure.

Preventive interventions

Since the late 1980s, multiple studies have evaluated HPV testing as an adjunct to cytology in screening programmes. These have considered HPV testing either as a triage test in cases of mild abnormalities or as a primary screening test. It is not the purpose of this paper to review this literature and excellent summaries are being regularly produced and updated (see later). In brief, triage studies have shown that HPV testing is more sensitive than repeated cytology in identifying underlying high grade lesions, whereas the specificity is age dependent. HPV tests show lower specificity than cytology in younger women, accounting for the higher sensitivity of HPV tests.

In terms of causality assessment, these studies showed that it is possible to predict the concurrent presence of neoplastic disease (usually HSIL, CIN 3, or severe dyskaryosis), or the risk of developing it, by means of HPV DNA detection. This property of the HPV test offers an indirect measurement of the strength of the association and of the temporal sequence of the events.

Determinants of HPV infection

Epidemiological studies investigating risk factors for HPV infection clearly and consistently have shown that the key determinants among women are the number of sexual partners, the age at which sexual intercourse was initiated, and the likelihood that each of her sexual partners was an HPV carrier. These are lifelong behavioural traits, thus clearly preceding the development of cervical cancer.

The role of men as possible vectors of HPV was measured in the early epidemiological studies by questionnaires that asked about the sexual behaviour of the husbands or sexual partners, the age at which sexual intercourse was initiated, and the likelihood that each of her sexual partners was an HPV carrier. These are lifelong behavioural traits, thus clearly preceding the development of cervical cancer.

The results need to be extended and confirmed in clinical studies. More importance for clinical and screening purposes, another study confirmed that high viral loads predicted cervical lesions and, more interestingly, that the reduction of viral load or clearance of viral DNA in repeated visits predicted regression of CIN lesions to normalcy. These studies suggest that measuring viral load, at least of HPV-16, may distinguish between clinically relevant infections and those that are unlikely to progress. However, in contrast to the above results one large prospective study in Portland USA, using quantitative hybrid capture, did not find viral load to be a determinant of risk of future CIN 3 (A Lorincz et al, unpublished data, 2002). More research is needed to validate these methods and the results need to be extended and confirmed in clinical studies.

Biological gradient

This refers to the presence of a dose–response curve indicating that the magnitude of the exposure is related to the risk of disease. This requirement, largely supported by chemically induced models of carcinogenesis, is difficult to apply in models of viruses and cancer. For HPV DNA, it is difficult to measure viral load in relation to the DNA of the cancer cells in the specimen, although early studies tended to show a correlation between HPV DNA amount and disease status. Some recent publications have provided relevant evidence using real time PCR methods. A study that used a nested case–control design found that cases consistently had higher viral loads for HPV-16 than controls, and that high viral loads could be detected up to 13 years before the diagnosis of cervical cancer. Women with high viral loads for HPV-16 had a 30 fold greater risk of developing cervical cancer than did HPV negative women. This also applied to women under the age of 25. A related paper using the same population showed that the 20% of the population with the highest viral loads for HPV-16 had a 60 fold higher risk of developing carcinoma in situ when compared with HPV negative women. Of importance for clinical and screening purposes, another study confirmed that high viral loads predicted cervical lesions and, more interestingly, that the reduction of viral load or clearance of viral DNA in repeated visits predicted regression of CIN lesions to normalcy. These studies suggest that measuring viral load, at least of HPV-16, may distinguish between clinically relevant infections and those that are unlikely to progress. However, in contrast to the above results one large prospective study in Portland USA, using quantitative hybrid capture, did not find viral load to be a determinant of risk of future CIN 3 (A Lorincz et al, unpublished data, 2002). More research is needed to validate these methods and the results need to be extended and confirmed in clinical studies.
The pattern of transcription changes as the lesion increases in severity. All open reading frames (ORFs) are expressed in early lesions but the expression of ORFs E4 and E5 is not found in many invasive cancers.\(^{(5)}\) (7) The E6 and E7 ORFs contain the transforming ability of HPV. These are always intact and are consistently expressed in cervical cancer cell lines, in cells transformed by HPV, and in HPV associated cancer tissue. They are transcribed at higher levels in high grade lesions than in low grade lesions.\(^{(6)}\) (8) In most cell lines and in many HPV associated cancers, the HPV DNA is integrated into the cellular DNA. HPV-18 is nearly always integrated, whereas HPV-16 can be found episomally or in the integrated form.\(^{(7)}\)

In reviewing work on the molecular genetics of cervical carcinoma, Lazo indicated different mechanisms of cancer induction. The effects of E6 and E7 on host regulatory proteins can be considered to be HPV related mechanisms. An additional effect could be expected from the consequences of viral integration and the specific impact on the integration sites. The third mechanism, which may or may not be related to HPV, is the accumulation of the cellular genetic damage needed for tumour development. The existence of this mechanism is strongly suggested by the observations of recurrent losses of heterozygosity and by recurrent amplifications in a large fraction of cervical carcinomas.\(^{(8)}\) The role of non-identified tumour suppressor genes is also suggested by experiments showing that the tumorigenicity of HeLa cells could be suppressed by fusion with normal fibroblasts or keratinocytes, and that the tumorigenicity of SiHa cells was suppressed by the introduction of chromosome 11 via microcell transfer technology.\(^{(9)}\) Similarly, the immortality of Hela and Sitta cells was suppressed by the introduction of chromosomes 3, 4, and 6.\(^{(10)}\)

Although a review of the field is far from the purposes of this discussion, it seems quite clear that the biology of cervical cancer in relation to HPV has become a paradigm of viral mediated oncogenesis. The work being regularly published has clearly shown that the viral DNA detected by epidemiological studies is not a passenger infection of the cancerous tissue, but a biologically meaningful association.
and reasons why a mostly benign infectious process sometimes results in malignancy. It must be understood by readers that the pathways discussed above promote the development of cervical cancer to any appreciable extent. Such differences between HPV types may seem surprising, given the high DNA and structural similarities. However, a large functional divergence caused by small genetic changes is the norm in many biological systems. Variations in carcinogenic potential among HPVs are principally governed by the E6 and E7 proteins; specifically by the capacities of these proteins to interact with and alter or destroy key cell cycle regulatory molecules.

The progress and outcome of an HPV infection depend on HPV type, anatomical location, and the nature and timing of local cellular and tissue influences. Establishment is tied to the tissue proliferative capacities of these proteins to interact with and alter or destroy key cell cycle regulatory molecules.

Persistence in keratinocytes is variable and related to viral type, anatomical location, and the nature and timing of local cellular and tissue influences. Virions access basal and parabasal cells in areas of erosion and viral DNA enters the cell nuclei. Establishment is tied to the tissue proliferative activity of epithelial cells and, in the case of extensive tissue repair, the viral infection can become widely disseminated. Persistence in keratinocytes is variable and related to viral type. Finally, integration of viral DNA may occur, resulting in lifetime persistence of certain viral genes in the cell. In the cervix, detectable infection by low risk HPV types is of relatively short duration, whereas infection by most high risk types lasts longer. On occasion, such infections may become persistent and last years or even decades; it is in these cases that the risk of cancer is increased.

The establishment of HPV infection can be modulated by a competent and primed immune system. In vitro experiments have revealed an inverse association between the degree of cervical neoplasia and interleukin 2 production by peripheral blood mononuclear cells in response to HPV-16 E6 and E7 peptides. Women with CIN 3 or cancer appear to have a decreased ability to mount a T helper cell type 1 (Th1) mediated immune response to HPV E6/E7, compared with women with CIN 1 or HPV infected women without lesions. It is possible that a Th1 mediated cellular immune response could play a role in host immunological control of HPV infection and that lack of such an appropriate response may predispose to the progression of cervical disease.

If HPV enters immature metaplastic basal stem cells that are actively dividing the infection can become widely dispersed and persistent. In contrast, if infection occurs only in the parabasal transit amplifying cells the infection may become transient or quasi-persistent. The size, histological grade, and duration of lesions can depend on the number and type of lesions that become infected by HPV. In either transient or persistent infection, there may be periodic viral genome amplification, depending on the activity of the infected daughter cells, which can lead to variable detection of the lesion by HPV DNA or Pap tests.

There is an important difference in host–virus interactions of carcinogenic HPV types and low risk HPV types—the former have activities that more strongly interfere with a set of host cell cycle control mechanisms. It is therefore useful to consider the effects of carcinogenic HPV types. HPV initially infects and activates cycling cells as p33–cyclin dependent kinase 2, which control progression through the cell cycle. E6 protein can overcome the p53 protective control pathways, which are important in preventing the genetic damage that may lead to cancer.

HPV genomes attach to host chromatin via the E2 protein and replicate at a steady state, once for each cell division. It has been speculated that a benefit of this tethered theta mode of replication is that the loss of HPV DNA from cells by non-disjunction is minimised and the presence of low amounts of HPV DNA in cells is less likely to be detected by the cellular interfernece mechanisms that could trigger apoptosis. As cells differentiate and move to the surface there is a normal differentiation and maturation process that leads to pyknotic condensed cells that slough from the tissue. However, in virally infected tissues there is activation of unscheduled DNA replication in some spinous cells, accompanied by a switch in viral DNA replication to the rolling circle mode, which leads to the production of viral progeny. This reactivation of DNA synthesis can be detected by the presence of punctate proliferating cell nuclear antigen tissue staining (a protein that binds with a key role in the nature and timing of HPV virions in a subset of upper layer cells.

HPV E7 proteins of both low and high risk types have an ability to promote unscheduled DNA replication in spinous cells. It is believed that the extent to which E7 stimulates cells, and the tissue location at which such stimulation occurs, is important to malignant progression. Spinous cells respond to E7 by the production of a cyclin kinase inhibitor, p21cip1, translated from sequestered RNA. In basal and parabasal cells existing mRNA for p21cip1 is not available and the protein is typically produced from new transcripts stimulated by p53; however, if p53 is inactivated by E6 the p21cip1 cannot be made. Spinous cells thus have a control advantage lacking in basal cells. Interestingly, high amounts of E7 can bind and block the activity of p21cip1. The relative amounts of E7 and p21cip1 are believed to determine whether cells re-enter S phase and replicate viral DNA or whether cells block viral production. The inspection of tissues reveals a mutually exclusive set of spinous cells with high amounts of either E7 or p21cip1. Cells in which E7 overcomes the p21cip1 block can become karyocytes and produce viral particles. This balance can explain the patchy expression of the HPV effect in infected tissues. A key function of the E6 oncoprotein is the destruction of p53, a protein that is activated upon phosphorylation via DNA damage sensing proteins. Activated p53 stops the cell cycle in the G phase as a result of direct stimulation of p21cip1 by this molecule. Alternatively, in the case of major DNA damage or high amounts of viral replication, p53 may activate an apoptotic pathway. E7 also interferes with alternative non-p53 dependent apoptotic pathways. Thus, in the case of E6 mediated destruction of p53, cells are unable to prevent the accumulation of genetic mutations. Cells have other defensive homeostasis mechanisms and interfere with counter functions, such as cdk/cyclin blocks and direct cells to enter S phase. Therefore, it appears that the development of malignancy is a consequence of an aberrant host–virus interaction. A potentially important event in this process is the aberrant regulation of E6/E7 expression. Low grade CIN lesions, E6/E7 expression is mainly found in differentiating spinous cells that have withdrawn from the cell cycle. In high grade CIN lesions and cervical carcinomas, strong E6/E7 expression is seen in the proliferating cell compartments.

HPV DNA is frequently integrated into the host genomes in cancers in such a way that the E2 repressor protein is inactive and allows overexpression of E6 and E7. In cases where HPV integration is not detected, other mutations can be shown in the E2 protein or in repressor functions, such as
HPV and cervical cancer

Y1 sites,206–208 which appear to allow continuous expression of the E6 and E7 oncoproteins. Yet another way in which E6 and E7 could be overexpressed in proliferating cells is by the generation of chimaeric HPV mRNAs encoding the E6 and E7 proteins that have host sequences at their 3′ termini. Such RNAs are frequently more stable and allow more protein to be synthesised.91

In persistent HPV lesions, viral genomes in the basal cells continue to stimulate the cells to ignore the DNA damage that may be accumulating.204,205 Cell stimulation by E6 and E7 of high risk carcinogenic HPV types produces clones with an extended life span that have passed a point called mortality 1 or M1, although the cells are still not immortal.191 An important step in immortalisation is related to telomeres. Normally, telomeres shorten every cell generation and once they reach a critical length the cells die. Telomere length is maintained by telomerase, which in combination with a capping function, can stabilise and even lengthen telomeres, allowing cells to continue dividing. E6 can activate telomerase and additional cell mutation(s) can then stabilise the telomeres and allow cells to pass a second stage called mortality 2 or M2. It is not known how many additional independent mutations are needed to transform immortalised cells fully to malignancy.91 One set of mutations allows the cell to break through the basement membrane by eliciting a set of novel proteases. Another mutation(s) allows cells to move in the dermis.206 Undoubtedly, metastatic cells have accumulated many additional mutations that allow them to create their own microenvironment for survival in foreign parts of the body.

Biological mechanisms of HPV carcinogenesis. Evaluation

The natural history of HPV infection and its relation to cancer development is being described by molecular technology. These investigations indicate that the induction of cancer by HPV is mediated by viral interference with essential regulatory mechanisms of cellular growth, DNA repair, and immunological escape. The alternative hypothesis of HPV being an opportunistic passenger in the tumoral tissue is no longer tenable.

Experimental evidence

Intervention studies in human populations would require the demonstration of a reduction in cervical cancer incidence and mortality following a reduction in the incidence of HPV infection in the underlying population. Prophylactic vaccines are being developed and vaccination trials are in advanced planning phases to evaluate such expected effects.

Review of the animal models for HPV related lesions, including cancer, is out of the scope of this report. In brief however, there are animal models of PV infections that induce warts and carcinoma in the skin, mucosa, and the digestive tract. The bovine PV (BPV) induces fibropapillomas in the skin and carcinoma of the digestive tract in animals exposed to bracken fern in their diets. Cottontail rabbit PV (CRPV) induces papillomas that could evolve into carcinomas either spontaneously or following the application of various promoters. Canine oral PV (COPV) causes oral papillomas that do not undergo malignant transformation. Several of these models are actively being used in the preparation of vaccines (for a review see Saveria Campo206 and Tindle).206 Many other papillomaviruses have been identified in animal models.208

Experimental evidence. Evaluation

Experimental evidence shows that species specific papillomaviruses induce papillomas and cancers in the susceptible host.

Analogy

Analogy is no longer viewed as an essential criterion for causality assessment. As proposed by Hill, analogy would allow several considerations in the HPV and cervical cancer model that could be mentioned:

1. If other DNA viruses (such as HBV) can induce cancer in humans, HPV could too.
2. If animal PVs can induce papillomas and carcinomas in several animal models, HPV could do the same in humans.
3. If viral products that interfere with p53 and RB in animal models, such as the simian virus 40 large tumour antigen (SV40 tag), induce cancers in animal species, HPV could do so in humans.

Analogy. Evaluation

The HPV and cervical cancer model is analogous to many other examples of PV induced papillomas and carcinomas and cancers caused by other viruses.

Exclusion of alternative explanations

In the early studies of HPV and cervical cancer, and currently in most studies, a fraction of cases are labelled as HPV negative and investigated under the hypothesis that HPV negative cases are a true biological entity.213,214 The proportion of such cases tends to be higher in studies of preinvasive neoplasia.213,214 As a consequence, there was some uncertainty in the interpretation of the results until the early 1990s.213,214 In many studies, HPV negative cases were frequently compared with HPV positive cases in relation to their epidemiological profile. In broad terms, it was clear that “HPV negative” cases retained the same traits as the rest of the cases (similar age, high number of sexual partners, young age at first sexual intercourse, long term use of contraceptives, high parity, etc). These results strongly suggested that the apparently HPV

Exclusion of alternative explanations. Evaluation

Alternative (non-HPV related) hypotheses to explain a fraction of cervical cancer are not being proposed. The hypothesis that a fraction of 5–10% of cases may occur in the absence of HPV should be retained for research purposes. Public health recommendations targeting a putative proportion of HPV negative cervical cancer cases are not supported by current results and are not justified.

Overall evaluation

Systematic review of the causality criteria strongly indicates that the association of HPV and cervical cancer is causal in nature. The association is very strong, consistent, specific, and universal. HPV infection precedes preinvasive disease and the evidence for biological plausibility of the association is persuasive beyond reasonable doubt.
negative cases were also related to an STD pattern; however, none of the known sexually transmitted agents that had occasion-ally been associated with cervical cancer is able to satisfy the causality criteria outlined in table 1. In the past decade there has not been a hypothesis supported by sound epidemiological or biological data indicating that the aetiology of cervical cancer could be independent of HPV.

It should be retained as a scientific and research option that the existence of some non-HPV related cervical cancer cases is plausible. The grounds for such a statement rely on the following facts: (1) Epithelial cells are capable of developing into cancer cells and cancer growths in all human tissues regardless of a known, viral or non-viral, cause. Thus, cells in the human cervix might have this capability too. (2) Cell genes that are involved in HPV related carcinogenesis should be able to generate spontaneous or induced mutations leading to cancer in the absence of HPV. Available evidence suggests that this event is rare within the life expectation of the human population. (3) Relatively few cases of cervical cancer in very old women have been investigated. It is likely that the non-HPV related cancers currently occur very rarely and probably cluster in very old women. (4) Non-epithelial cancers do occur in the cervix at a low frequency.

ALTERNATIVE MODELS OF CERVICAL CANCER AETIOLOGY

This section will discuss in some detail the role of factors other than HPV in cervical cancer and evaluate them under Rothman’s model of necessary and sufficient causality.

Other risk factors for cervical cancer

Most of the sexual behaviour parameters that were linked to cervical cancer in the past are being re-evaluated in studies that considered the strong influence of the presence of HPV biomarkers. Soon after the introduction of HPV testing into research protocols, it became clear that some of the key risk factors that reflected sexual behaviour, such as the number of sexual partners, merely reflected the probability of HPV exposure. Other factors, such as the estimates of age at first exposure (as indicated by age at first sexual intercourse or at first marriage) are still under evaluation. In addition, several environmental factors that were historically related to cervical cancer are currently being assessed. These include hormonal factors (use of OCs and multiparity) and dietary factors. A special consideration should be given to exposure to HIV and to other situations of immunosuppression, which will not be dealt with in detail in this discussion.

Investigation of the role of such factors, once the central role of HPV was recognised, generated an analytical situation with regard to the protocol, test- ing system, and some of the key results have been described in the country specific publications. The pooled analyses for each risk factor will support their conclusions on analysis restricted to HPV positive cases and controls. For this discussion, we will summarise the key preliminary findings.

Oral contraceptives

The IARC multicentre study included 1768 cases and 262 controls that were positive for HPV DNA. OC use “ever” was associated with a significant increase in risk (OR = 1.47; 95% CI, 1.02 to 2.12). Use of OCs for less than five years was not related to cervical cancer (OR = 0.77; 95% CI, 0.46 to 1.29). The risk increased for five to nine years of use (OR = 2.72; 1.36 to 5.46) and for more than 10 years (OR = 4.48; 2.24 to 9.36). The conclusion of this analysis indicates that the use of OCs for five or more years is a cofactor that increases up to fourfold the risk of cervical cancer among women who are carriers of HPV DNA. These results provide a consistent summary of the previous publications of the individual studies included in the multicentre project.

The evidence for an association of cervical cancer with the use of oral or other hormonal contraceptives is not entirely consistent. Several studies that investigated HPV positive women found no associations or only weak associations in subgroup analyses. These apparently conflicting results may reflect the increased cytological surveillance of women who are taking OCs in developed countries and the use of different case definitions (from ASCUS up to HSIL/CIN 3 as opposed to cervical cancer) in cohort studies.

The IARC monograph programme reviewed the evidence for OCs and concluded that, for the associations with cervical cancer, biases related to sexual behaviour, screening, and other factors could not be ruled out as possible alternative explanations. One of the difficulties encountered in the conduct and analysis of epidemiological studies is the proper assessment, through questionnaires, of the correlates of HPV exposure (sexual behaviour) and screening history. However, OCs were evaluated as human carcinogens (class 1) by the monograph because of the evidence linked to liver cancer.

Because of the potential public health importance of confirming an association between the long term use of OCs and HPV infections in the development of cervical cancer, efforts are now being devoted to confirm the results in different populations.

Parity

In the IARC multicentre study, HPV positive women who reported seven or more full term pregnancies had a fourfold increased risk of cervical cancer compared with similar HPV positive women who were nulliparous (OR, 3.8; 95% CI, 2.7 to 5.3). There was still a twofold increased risk when women reporting seven or more pregnancies were compared with HPV positive women who reported one to two full term pregnancies.

Similar results were obtained in Costa Rica, Thailand, and among women with preinvasive disease in the Portland study. In Denmark and in the Manchester cohort study, two populations with low parity, the effects were less visible. In another high parity country—Honduras—the effects of parity were not significant among the HPV positive cases and controls.

Smoking

Smoking has been related to cervical cancer since the late 1970s, based upon the correlations seen between cervical cancer incidence and the incidence of other tobacco related cancers. The 1986 IARC monograph on smoking considered that the evidence available for cervical cancer was insufficient to rule out confounding with sexual behaviour traits, strongly
related to both smoking and cervical cancer. An extensive review of the relation between smoking and cervical cancer was published in 1998, including eight cohort and 44 case–control studies. The report concluded that the association was largely consistent in studies that adjusted for HPV DNA or restricted analyses to HPV positive women. The magnitude of the risk for current smokers was of the order of one to threefold; the ORs tended to be higher in more advanced preinvasive neoplasia, and in several studies a dose–response relation with the amount of tobacco consumed was seen. A recent review of the evidence conducted by the Surgeon General in the USA retained the hypothesis that a causal association between cigarette smoking and cervical cancer was plausible. However, the report indicated that the extent to which cigarette smoking could be considered independent of HPV could not be definitively assessed.

Restricting the review to studies that evaluated HPV exposed women, the preliminary pooled results of the IARC multicentre study found that “ever smoking” was associated with a twofold, significantly increased risk of cervical cancer, with a significant dose–response (M Plummer et al, unpublished, 2002). These findings are consistent with those found for “current v never smoking” among HPV positive women in the Costa Rica study (OR = 2.3), the Portland study (OR = 2.7 for CIN 2–3), the Copenhagen study (OR = 1.9), and the Manchester study (OR = 2.2). These recent studies are providing growing evidence on the carcinogenic effect of cigarette smoking in women with HPV infection. However, the mechanisms by which cigarette smoking may affect cervical cancer (such as a direct effect of the tobacco metabolites, or an indirect effect related to tobacco induced immunosupression or to reduced dietary antioxidants) remain elusive and further studies are warranted.

The general considerations in relation to any of the cofactors considered and the carcinogenic effects of HPV are threefold. First, in the analyses restricted to HPV positive women, the magnitude of the RR estimates are moderate (range 2 to 6 for extreme categories of exposure) for any of the variables when compared with the risk estimates for HPV (ranges 50 to > 500). Second, the results in the literature concerning these factors remain inconsistent, again in contrast to the striking consistency of the associations found for HPV DNA. Third, the interpretation of the risk estimates for cofactors should be complex (HLA) types and p53 polymorphisms are being actively investigated because of the indication that they may play a role in the natural history of HPV infections. The putative effect of such individual susceptibility factors is not adjusted for in the risk analyses of the environmental factors. However, at this stage, there is limited information to substantiate an effect of these host factors as independent of HPV.

There is a clear need to pursue research in understanding the factors that determine whether a woman with an HPV infection will clear the infection or become a persistent carrier. Furthermore, studies are still needed to explore whether additional factors play a role in determining neoplastic progression and how best to use them in screening and patient management.

**Likely components of sufficient causes of cervical cancer**

The purpose of this section is to try to substantiate the components of plausible sufficient causes of cervical cancer period. The prognosis of the EBV infection in relation to Burkitt’s lymphoma is related to age at first infection and probably to the concurrent exposure to malaria. Similarly, most studies have shown that the risk of cervical cancer is related to age at first sexual intercourse. More recent studies that included HPV measurements have shown age at first intercourse to be a surrogate measure of age at first HPV exposure. However, definite evidence that cervical cancer progression is linked to age at first HPV exposure has not been provided. It has been proposed that the developing cervix (at the age of peri-menarche) or the healing cervix (as a consequence of deliveries, cervical trauma, or any other STD infection) are high risk situations for an HPV infection to reach the basal layer and establish a persistent infection.

Some STDs, including HIV, have repeatedly been found to be associated with cervical cancer. The multicentre study found a twofold increased risk for the presence of antibodies to *C. trachomatis* (OR = 2.1; 95% CI, 1.1 to 4.0). Antibodies to HSV-2 and non-specific inflammatory changes have also been related to modest increases in risk among HPV positive women. Other environmental risk factors under evaluation are socioeconomic status and nutritional factors.

**Limitations of the evidence**

One limitation of the available studies and of the summary presented here is the crudeness of information available on variables that may modulate the effect. This makes it difficult to explain in finer detail the geographical variation in cervical cancer incidence and the variability in risk estimates reported in different populations. For example, the inconsistencies in finding associations of cervical cancer with the use of OCs may be explained by factors related to the intensity, duration, or the chemical composition of the exposure. Factors that are largely country specific, such as the variability in time since widespread introduction, availability of combined versus sequential products, oestrogen/progesterone doses, etc, could be important determinants; yet these would only partially account for the associations observed.

A second limitation is that many studies did not consider host factors in relation to HPV. Human major histocompatibility complex (HLA) types and p53 polymorphisms are being actively investigated because of the indication that they may play a role in the natural history of HPV infections. The putative effect of such individual susceptibility factors is not adjusted for in the risk analyses of the environmental factors. However, at this stage, there is limited information to substantiate an effect of these host factors as independent of HPV.

There is a clear need to pursue research in understanding the factors that determine whether a woman with an HPV infection will clear the infection or become a persistent carrier. Furthermore, studies are still needed to explore whether additional factors play a role in determining neoplastic progression and how best to use them in screening and patient management.

**Table 5** Risk factors for cervical cancer among human papillomavirus positive women

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Risk exposure</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV DNA in cervical exfoliates</td>
<td>Positive for high risk types</td>
<td>Negative</td>
</tr>
<tr>
<td>Use of oral contraceptives</td>
<td>5 or more years of use</td>
<td>Never</td>
</tr>
<tr>
<td>Smoking</td>
<td>Ever</td>
<td>Never</td>
</tr>
<tr>
<td>Parity</td>
<td>5 or more pregnancies</td>
<td>None or 1–2</td>
</tr>
</tbody>
</table>

*References adapted from the results of the IARC multicentre study.*
according to Rothman’s scheme,\textsuperscript{11} and based upon data from large series of cases examined with reliable HPV DNA testing systems. In the literature on cervical cancer, the independent risk factors that have been repeatedly identified and at least partially confirmed by some of the most recent studies could be simplified to a dichotomous categorisation (table 5).

Table 6 shows the distribution of approximately 2500 cases of invasive cervical cancer from over 25 countries classified according to their exposure to every possible combination of the four factors considered above. Approximately 1500 of these cases were included in the IARC multicentre study\textsuperscript{12} and approximately 800 cases included in the IBSCC tested for human papillomavirus (HPV) DNA in 1995 and 1999.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV</td>
<td>341</td>
<td>186</td>
<td>186</td>
</tr>
<tr>
<td>HPV + OC</td>
<td>54</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>HPV + Smk</td>
<td>115</td>
<td>96</td>
<td>978</td>
</tr>
<tr>
<td>HPV + OC + Smk</td>
<td>587</td>
<td>302</td>
<td>322</td>
</tr>
<tr>
<td>HPV + OC + Preg</td>
<td>20</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>HPV + Smk + Preg</td>
<td>72</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td>HPV + OC + Smk + Preg</td>
<td>223</td>
<td>82</td>
<td>88</td>
</tr>
<tr>
<td>OC</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>OC + Smk</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>OC + Preg</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>OC + Smk + Preg</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Smk</td>
<td>8</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Smk + Preg</td>
<td>9</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Preg</td>
<td>15</td>
<td>21</td>
<td>1</td>
</tr>
<tr>
<td>None of the four</td>
<td>23</td>
<td>25</td>
<td>2</td>
</tr>
<tr>
<td>Total number of cases</td>
<td>1490</td>
<td>806*</td>
<td>806*</td>
</tr>
</tbody>
</table>

*The total number in the column is not 806 because of missing values in some of the variables. References: study 1, Muñoz et al (2000);\textsuperscript{32} study 2, Bosch et al (1995);\textsuperscript{34} study 3, Walboomers et al (1999).\textsuperscript{216} HPV, HPV DNA positive; OC, duration of use of hormonal contraceptives >6 years; Preg, >3 pregnancies (live or still born); Smk, smoker (ever). IARC, International Agency for Research on Cancer; IBSCC, international biological study on cervical cancer.

Using these distributions as a realistic guide, some theoretically sufficient causal models could be proposed as plausible for cervical cancer (table 7).

Each combination of factors as described could theoretically lead to cervical cancer and, under each model, the occurrence of the disease may be further modulated by the presence or absence of the additional factors. These may determine parameters such as the age of onset, the aggressiveness, or other characteristics of tumour behaviour.

Some of the categories in table 6 are compatible with the hypothesis that a fraction of cases of cervical cancer (4–7%) are independent of HPV and even that some 1–2% are independent of the four environmental risk factors considered in table 6, either alone or in combination. To explain these groups, two alternatives could be considered.

The first alternative is that some cervical cancer cases truly occur unrelated to any of the combinations of the four factors considered. Some previous analyses that have compared the epidemiological profile of HPV positive and apparently HPV negative women with cervical cancer did not find significant differences in their sexual or reproductive behaviour. These types of analyses were reported at the time that HPV DNA detection technology was of limited sensitivity and 30–40% of cervical cancer cases were reported as HPV negative.\textsuperscript{1} Therefore, the HPV unrelated hypothesis would argue in favour of a role for other STDs. Current results of some major
studies found small and still inconsistent effects from previous exposures to *C. trachomatis* and/or HSV-2 infections (J Smith et al, unpublished data, 2002). However, these effects are mostly seen in the presence of HPV DNA.

Conversely, the distributions presented in table 6 may still suffer from misclassification of any of the variables considered, notably of HPV. A particularly relevant exercise was undertaken to verify technical HPV misclassification with the cases included in the IBSCC study (studies 2 and 3 of table 6). After the key results were published reporting an HPV DNA prevalence of 93.0%, the apparently HPV negative cases were further investigated. The second level evaluation included: (1) A comparison of the serological and epidemiological profiles of the “HPV DNA negatives” compared with the “HPV DNA positives”. (2) The pathology of the specimen was reviewed. Furthermore, serial cuts from the paraffin wax blocks were used to ensure that the specimen used for HPV DNA testing included neoplastic tissue. (3) A different technology was used for HPV DNA testing using shorter primers in the E7 region and two sets of consensus primers (CP/II and GPS+6+). In brief, the results of the study illustrated that most of the HPV negative cases were in fact HPV positive, and that the HPV types newly identified were the common types, with an over-representation of HPV-18. The distribution of risk factors in study 3 of table 6 thus represents the conclusion of the large IARC effort in HPV and cervical cancer. Based upon the final results of this study and the considerable body of evidence accumulated from other studies at the time, it was proposed that HPV DNA is a necessary cause of cervical cancer and that HPV DNA belongs to (is a component of) all reasonably conceived environmental sufficient causes.

The key consideration from this discussion, however, is that with the current degree of understanding it would be difficult to justify an aetiological model that would not include HPV DNA for most cervical cancer cases occurring worldwide. On these grounds, HPV fulfills the criteria of a necessary cause of cervical cancer.

The second qualifier of the evaluation in Rothman’s scheme refers to the sufficient criteria. From natural history studies, it is clear that a large fraction of HPV infections occur as a self limiting subclinical process with little impact on morbidity. The exceptions are the fraction of infected women in whom HPV persistence is established, and in whom the risk of cervical neoplasia increases significantly. Because of the large pool of infections that will not progress to cancer, it is usually accepted that HPV is not a sufficient cause of disease (it is noteworthy that no accepted cause of cancer has ever been considered as sufficient). The implication has been that other factors that modulate the evolution of the relevant HPV infection are intervening. However, specific evidence on the nature of these factors is elusive.

From the data in tables 6 and 7 it is clear that in a fair number of cases HPV is the only environmental factor identified of the four evaluated. This accounts for 23% (341 of 1490) of the cases in the multicentre study and 23% (186 of 806) of the cases in the IBSCC study. It is thus plausible that in perhaps one quarter of cases, the additional factors that modulate the host response to HPV are not the environmental factors usually linked to cervical cancer. It is probable that some of the host response mechanisms to the virus are the determinants of the prognosis of a given infection to either spontaneous resolution or to viral persistence and neoplastic progression.

The identification and natural history of biomarkers related to the immune response and host susceptibility to HPV is a subject of active research. Likewise, the criteria of causality outlined in table 1 may require a revision to integrate criteria for host responses in addition to the canopy of environmental risk factors.

### RECOGNITION OF THE CAUSAL LINK BETWEEN HPV DNA AND CERVICAL CANCER

The evidence for a qualification of the association between cervical cancer and HPV DNA as causal and the justification for intervention strategies based upon this conclusion were debated in the late 1980s and early 1990s. At the time, the HPV testing systems suitable for use in large epidemiological studies had limited sensitivity and specificity. The results generated were difficult to interpret and skepticism was overtly expressed in the international literature.

In 1989, one IARC scientific publication still retained the hypothesis that HPV DNA could be a passenger and that superinfection of the neoplastic tissue could not be safely ruled out as an alternative explanation. In 1992, a follow up publication again reviewed the evidence and concluded that previous incoherent epidemiological results could be explained by measurement errors in HPV detection. The review concluded that bias, chance, or confounding in the epidemiological studies could be safely ruled out and that the association could be considered causal in nature. In 1995, a formal IARC monograph was convened to review available evidence for HPV and cervical cancer and concluded that HPV-16 and HPV-18 were carcinogenic to humans and the two types were classed as group I carcinogens.

The conclusion of the 1995 monograph was subsequently endorsed by the scientific community at large, which uses the IARC’s reference widely as the standard for causality. Other relevant bodies have undertaken similar exercises and have consistently reached similar conclusions. These include the Centers for Disease Control, the National Cancer Institute (National Institutes of Health), the American Cancer Society (Cervical Cancer Resource Center), the American College of Obstetricians and Gynecologists, the US Department of Health and Human Services, the Program for Appropriate Technology in Health, the World Health Organisation, the European Research Organisation on Genital Infection and Neoplasia, and the Health Technology Assessment of the UK, among others.

In addition to the formal reviews by institutional groups, individual scientists and peer reviewed journals have repeatedly expressed their understanding on the causal nature of the association between HPV and cervical cancer.

### From evidence to decisions

Decision making in public health is a process that uses scientific evidence in addition to judgment and socioeconomic considerations. The turning point at which public health decisions are taken and enforced as opposed to recommending additional research is often elusive. The role of scientists in influencing such decisions is also debatable (for an extensive

---

**Likely components of sufficient causes of cervical cancer. Evaluation**

HPV is a necessary, non-sufficient cause of cervical cancer. In perhaps a quarter of a large series of cervical cancer cases, HPV was the only environmental risk factor identified. It is likely that the additional factors that combine with HPV to complete a sufficient cause in such cases are of endogenous rather than of environmental nature.
review see the special edition of the *American Journal of Epidemiology* 214.

Rothman’s textbook describes a rather extreme dichotomy between scientists and public health policy makers: 

“Lanes (1985) 215 has proposed that causal inference is not part of science at all, but lies strictly in the domain of public policy. According to this view, since all scientific theories could be wrong, policy makers should weigh the consequences of actions under various theories. Scientists should inform policy makers about scientific theories, and leave the choice of a theory and an action to policy makers. Not many public health scientists are inclined toward such a strict separation between science and policy, but as a working philosophy, it has the advantage of not putting scientists in the awkward position of being advocates for a particular theory.” 216

Indeed, history shows that skepticism is preferable in science. 

The field of cervical cancer prevention is now in an active phase of evaluation of novel technologies, to increase the efficiency of screening in developed populations and to offer realistic options to populations that do not benefit from cytology based organised programmes. The recognition that HPV is the causal agent of cervical cancer worldwide is a landmark achievement that sets the grounds for qualitative progress. Current efforts in cervical cancer prevention in relation to HPV are focusing first on the evaluation of protocols for HPV testing in the context of established screening programmes, secondly on developing HPV vaccines for the prevention and treatment of HPV infections, and thirdly on the development of HPV treatments. 

**CONCLUSION**

At the current level of knowledge, the causal role of persistent HPV infections in the development of cervical cancer and its precursors has been proved beyond reasonable doubt. A large number of human studies have been conducted following standard criteria that reasonably excluded bias, chance, and confounding in the estimation of the risk. The evidence available at this time is consistent with the established criteria of causality. The association of HPV with cervical cancer has been proposed as the first ever described necessary cause of a human cancer. 

At the turning point following a major discovery in the origin of cervical cancer, it is the responsibility of the public health administrators to judge when the scientific evidence is sufficient to take action and promote changes in medical practice.

Selected quotes from Sir Bradford Hill, subsequently endorsed by MacMahon and Pugh, 14 Weed, 15 and Rothman, 16 may illustrate the current situation in relation to the adoption of HPV testing as a relevant strategy for the prevention and management of cervical neoplasia. 

“Finally, like Hill before them, they (MacMahon and Pugh) believed that ‘proof’ of cause was elusive, and in the face of controversy, the crucial decision was one involving the point at which prudent action should reign and action should be taken, rather than waiting for more evidence.” 

“The failure of some researchers to recognize the theoretical impossibility of ‘proving’ the causal nature of an association has led to fruitless debates pitting skeptics who await such proof against scientists who are persuaded to make an inference on the basis of existing evidence.”

The responsibility of scientists for making causal judgments was Hill’s final emphasis in his discussion of causation: 

“All scientific work is incomplete—whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time.”

Acknowledgements

This work has been partially supported by research grant FIS 01/1237 and a non-restricted collaborative research agreement between the Institut Català d’Oncologia (ICO) in Barcelona, Spain and Digene Corporation in Gaithersburg, Maryland, USA. Advanced versions of this text have been reviewed by a number of researchers in the field of the viral aetiology of cervical cancer. Their comments and contributions are deeply appreciated: LA Brinton, National Cancer Institute, Bethesda, USA; TR Broker, University of Alabama, Birmingham, USA; RD Burk, Albert Einstein College of Medicine, New York, USA; X Castellsagué, Catalan Institute of Oncology, Barcelona, Spain; J Cuzick, Imperial Cancer Research Foundation, London, UK; S de San José, Catalan Institute of Oncology, Barcelona, Spain; M Del Vecchio, Digene Corporation, Gaithersburg, USA; Elf Franco, McGill University, Montreal, Canada; S Franceschi, International Agency for Research on Cancer, Lyon, France, I Frazer, Center for Immunology and Cancer Research, Brisbane, Australia; R Herrero, Proyecto Epidemiológico Guanacaste, San José, Costa Rica; S Krüger Kjær, Danish Cancer Society, Copenhagen, Denmark; CIN Lacey, Imperial College School of Medicine, London, UK; DR Lowy, National Institutes of Health, Bethesda, USA; V Moreno, Catalan Institute of Oncology, Barcelona, Spain; A Muñoz, John Hopkins School of Hygiene and Public Health, Baltimore, USA; M Plummer, International Agency for Research on Cancer, Lyon, France; WC Reeves, Centers for Disease Control and Prevention, Atlanta, USA; M Schaliman, National Cancer Institute, Bethesda, USA; JT Schiller, National Cancer Institute, Bethesda, USA; H-R Shin, National Cancer Centre Research Institute, Kyonggi, Korea; J Smith, International Agency for Research on Cancer, Lyon, France; PIF Snijders, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; BM Steinberg, Long Island Jewish Hillside Medical Center, New York, USA; MH Stoler, University of Virginia, Charlottesville, USA; D Thomas, Fred Hutchinson Cancer Research Center, Seattle, USA; H Vainio, International Agency for Research on Cancer, Lyon, France; AJ van den Brule, Free University Hospital, Amsterdam, The Netherlands; LL Villa, Ludwig Institute for Cancer Research, Sao Paulo, Brazil; TC Wright, Columbia University, New York, USA. Many other researchers have contributed to understanding cervical cancer aetiology and to this review with their work, presentations at meetings, and coffee break discussions. We are grateful to them and hope this review is of use to anyone involved in the task of cervical cancer prevention. Many thanks to M Díaz and E Guinó for statistical support and to C Rajo and M González, for secretarial help.

Authors’ affiliations 

F X Bosch, Institut Català d’Oncologia, Servei d’Epidemiologia i Registre del Cancer, Gran Via Km 2.7 S/n 08907 L’Hospitalet de Llobregat, 08907 Barcelona, Spain

A Lorincz, Digene Corporation, 1201 Clopper Road, Gaithersburg, MD 20878, USA

N Munoz, International Agency for Research on Cancer (IARC), Unit of Field and Intervention Studies, 150 Cours Albert-Thomas, F-69372 Lyon, Cedex 08, France

J L M Meijer, Vrije Universiteit Medical Center, Department of Pathology, De Boelelaan 1117, PO Box 7057–1007, 1081 HV Amsterdam, The Netherlands

K V Shah, The John Hopkins School of Public Health, Department of Molecular Microbiology and Immunology, 615 North Wolfe Street, Baltimore, MD 21205, USA

This paper is dedicated to the memory of the late Jan M M Walboomers.

**REFERENCES**


HPV and cervical cancer 261


HPV and cervical cancer


274 Multiple authors. From epidemiology to policy: a symposium on the translation of epidemiologic evidence into public health policy. Am J Epidemiol (Special Issue) 2001;154.


The causal relation between human papillomavirus and cervical cancer

F X Bosch, A Lorincz, N Muñoz, C J L M Meijer and K V Shah

*J Clin Pathol* 2002 55: 244-265
doi:

Updated information and services can be found at:
http://jcp.bmj.com/content/55/4/244

These include:

**References**
This article cites 221 articles, 43 of which you can access for free at:
http://jcp.bmj.com/content/55/4/244#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/